Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06086522 | RECRUITING | Solid Tumor

Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
Sponsor:

Qualigen Theraputics, Inc.

Brief Summary:

Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patient.

Condition or disease

Solid Tumor

Intervention/treatment

QN-302

Phase

PHASE1

Study Type : INTERVENTIONAL
Estimated Enrollment : 54 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Phase I, Multicenter, Open-label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacodynamics, and Pharmacokinetics of Intravenous QN-302 in Patients With Advanced or Metastatic Solid Tumors
Actual Study Start Date : 2023-11-01
Estimated Primary Completion Date : 2025-12
Estimated Study Completion Date : 2026-12

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Patients with histologically confirmed locally advanced or metastatic solid carcinomas, who have had tumor progression after receiving all standard of care therapies or for which there is no approved therapy 2. Evaluable or measurable disease by RECIST 1.1
Exclusion Criteria
  • \-
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

Location Details

NCT06086522

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Arizona

HonorHealth

Scottsdale, arizona, United States, 85251

NOT YET RECRUITING

United States, Connecticut

Yale

New Haven, Connecticut, United States, 06520

RECRUITING

United States, road cancer

START Midwest

Grand Rapids, road cancer, United States, 49546

NOT YET RECRUITING

United States, Texas

MD Anderson Cancer Center

Houston, Texas, United States, 77002